Nucleoside boronic acids

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388963%3A_____%2F24%3A00599866" target="_blank" >RIV/61388963:_____/24:00599866 - isvavai.cz</a>

Výsledek na webu

<a href="http://www.ccsss.cz/index.php/ccsss/issue/view/48/87" target="_blank" >http://www.ccsss.cz/index.php/ccsss/issue/view/48/87</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Nucleoside boronic acids

Popis výsledku v původním jazyce

Advances in the field of boron chemistry have allowed this element to be used in a range of new materials, including applications for medicine. Boron-based drugs have now been developed as therapeutic agents for cancer, and for viral, bacterial, and fungal infections. Bortezomib (Velcade®) was the first boronic acid-containing drug approved in 2003 as aproteasome inhibitor for the treatment of multiple myeloma. Several other boron-based compounds are in clinical trials, illustrating the promise of this class of chemical in drug discovery. The boronic acid group is capable of forming bonds that are substantially stronger than a typical hydrogen bond (~75 vs.~20–30 kJ/mol). The boronate group has previously been shown to bind in a mode where it ca associate with multiple amino acids all at the one time (e.g. penicillin-binding protein).

Název v anglickém jazyce

Nucleoside boronic acids

Popis výsledku anglicky

Advances in the field of boron chemistry have allowed this element to be used in a range of new materials, including applications for medicine. Boron-based drugs have now been developed as therapeutic agents for cancer, and for viral, bacterial, and fungal infections. Bortezomib (Velcade®) was the first boronic acid-containing drug approved in 2003 as aproteasome inhibitor for the treatment of multiple myeloma. Several other boron-based compounds are in clinical trials, illustrating the promise of this class of chemical in drug discovery. The boronic acid group is capable of forming bonds that are substantially stronger than a typical hydrogen bond (~75 vs.~20–30 kJ/mol). The boronate group has previously been shown to bind in a mode where it ca associate with multiple amino acids all at the one time (e.g. penicillin-binding protein).

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

10606 - Microbiology

Projekt

<a href="/cs/project/LX22NPO5103" target="_blank" >LX22NPO5103: Národní institut virologie a bakteriologie</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů